This week has seen two readouts for rivals from Clovis Oncology and Pfizer in prostate cancer – one of several indications on the Lynparza (olaparib ... the final label with the FDA.

CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development ... acetate, olaparib or 177Lu-PSMA ...

AstraZeneca and partner Merck & Co look set to have a much narrower label ... The FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted by 11 to one that Lynparza (olaparib) should be ...

evaluating pocenbrodib alone and with other drug combinations. The first patent has been dosed in the phase 1b/2a clinical trial P300-02-001, which is evaluating pocenbrodib alone, and in combination ...

AstraZeneca’s Imfinzi receives US FDA approval for patients with muscle-invasive bladder cancer: Cambridge, UK Tuesday, April 1, 2025, 10:00 Hrs [IST] AstraZeneca’s Imfinzi (d ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

The approval was granted by the Food and Drug Administration (FDA ... NIAGARA is a randomized, open-label, multi-center, global Phase III trial evaluating perioperative IMFINZI as treatment ...

FDA approvals exist for monotherapy with rucaparib for those with BRCA1 or BRCA2 mutated mCRPC, while olaparib has a broader label for patients with pathogenic mutations in any one of 14 homologous ...

Olaparib can be ... However, the FDA has requested that Clovis Oncology limit the indication of Rubraca as second-line maintenance therapy in recurrent ovarian cancer. The proposed changes to ...